Regulatory Novartis secures pair of regulatory wins for skin disease and malaria treatments Pharmaceutical TechnologyNovartis' Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification.Read full story pharminent April 27, 2026 (Last updated: April 27, 2026) Pharmaceutical Technology Novartis’ Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: New NIHR-funded TRC for Parkinson’s diseaseNext: Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis Related Stories Regulatory Moderna flu vaccine wins unanimous support from FDA panel pharminent June 18, 2026 Regulatory GSK claims FDA okay for first oral carbapenem antibiotic pharminent June 18, 2026 Regulatory uniQure sets course to US filing for Huntington gene therapy pharminent June 17, 2026
